

COMPANY PROFILE

Fresenius is a global healthcare group. We offer system-critical products and services for leading therapies for care of critically and chronically ill patients. The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Companies Fresenius Vamed and Fresenius Medical Care.

FRESENIUS GROUP IN FIGURES

€ in millions	FY/23	FY/22	Change
Revenue and Earnings			
Revenue ¹	22,299	21,532	4%
EBIT ^{1,2}	2,262	2,190	3%
Net income ^{1,2,3}	1,505	1,729	-13%
Earnings per share in € ^{1,2,3}	2.67	3.08	-13%
Balance sheet and cash flow			
Total assets	45,284	76,400	-41%
Non-current assets	32,764	58,121	-44%
Equity ⁴	19,651	32,218	-39%
Equity ratio ⁴	43%	42%	
Net debt/EBITDA ¹	3.76x	3.80x	
Investments ^{1,6}	1,346	2,015	-33%
Operating cash flow ¹	2,131	2,031	5%
Operating cash flow in % of sales	9.6%	9.4%	
Profitability			
EBIT margin ^{1,2}	10.1%	10.2%	
Return on equity after taxes (ROE) ^{1,2,3}	7.9%	8.5%	
Return on invested capital (ROIC) ^{1,2}	5.2%	5.6%	
Employees ¹	193,865	188,876	

¹ Prior-year figures have been adjusted due to the application of IFRS 5 to the deconsolidated operations of Fresenius Medical Care

² Before special items


³ Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

⁴ Including noncontrolling interests

⁵ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend

⁶ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE



¹ Deconsolidation of FMC completed on November 30, 2023

OPERATING COMPANIES

€ in millions		FY/23	FY/22	Change
FRESIENUS KABI	Revenue	8,009	7,850	2%
	EBIT ¹	1,145	1,080	6%
FRESIENUS HELIOS	Revenue	12,320	11,716	5%
	EBIT ¹	1,232	1,185	4%

¹ Before special items

INVESTMENT COMPANY

€ in millions		FY/23	FY/22	Change
FRESIENUS VAMED	Revenue	2,356	2,359	0%
	EBIT ¹	-16	20	--

¹ Before special items


REVENUE BY REGION



FY/23: €22.3 billion


- ▶ **Fresenius Kabi** specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes bio-pharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
- ▶ **Fresenius Helios** Europe's leading private health care provider. The company comprises Helios Germany and Helios Spain. Helios Germany operates more than 80 hospitals, about 230 outpatient care centers with 600 accredited doctor's licenses, six prevention centers and 27 occupational medicine centers. Helios Spain operates 58 hospitals, including eight in Latin America, 100 outpatient centers and around 300 occupational risk prevention centers.
- ▶ **Fresenius Vamed** internationally manages projects and provides services for hospitals and other health care facilities and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, design planning, medical and hospital engineering as well as construction, via maintenance and technical management to total operational management and high-end services.

REVENUE BY BUSINESS SEGMENT



FY/23: €22.3 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (December 31, 2023)	563,237,277
Market capitalization (December 31, 2023)	€15.8 billion

GROUP OUTLOOK 2024

	Targets 2024	Base 2023 ²
Revenue, growth (organic) excl. FMC	3 – 6%	€21,776 million
EBIT growth ^{1,2} (cc) excl. FMC	4 – 8%	€2,220 million

¹ Before special items
² Base 2023 adjusted

For the outlook of the business segments please see the Investor News of February 21, 2024.


FINANCIAL CALENDAR

	Dates
Report on 1st quarter 2024	May 8, 2024
Annual General Meeting	May 17, 2024
Capital Markets Day	June 5, 2024
Report on 1st half 2024	July 31, 2024
Report on 1st–3rd quarter 2024	November 6, 2024

Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows

ANALYST RECOMMENDATIONS


Equal-weight/Hold/
Neutral 32%



Buy/Outperform/
Overweight 68%

As of February 12, 2024

FINANCING MIX OF THE FRESENIUS GROUP



December 31, 2023: ~€15.8 billion


CONTACT



Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.de

Markus Georgi
Senior Vice President
Investor Relations
Telephone: +49 (0) 61 72/6 08-24 85
Telefax: +49 (0) 61 72/6 08-24 88

Follow us on Social Media:

 [linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)

 twitter.com/Fresenius_IR

For more information please see the imprint on our corporate website.